TABLE 1.

Overview of the clinical studies used in this analysis

Type of study and countriesVaccine groupsaPrimary vaccinationBooster vaccination
StudyReferencesScheduleNo. of children vaccinatedStudyReference(s)Schedule (mo)No. of children vaccinated
PHiD-CV vaccination studies
    Finland, France, PolandPHiD-CV + DTPa-HBV-IPV/Hib; 7vCRM + DTPa-HBV-IPV/HibA (study 001)6, 24, 462, 3, 4 mo1,650D (study 007)6, 24, 4612-181,112
    Germany, Poland, SpainPHiD-CV + DTPa-HBV-IPV/Hib + MenC-CRM; PHiD-CV + DTPa-HBV-IPV/Hib + MenC-TT; PHiD-CV + DTPa-HBV-IPV + Hib-MenC-TT; 7vCRM + DTPa-HBV-IPV + Hib-MenC-TTB (study 011)6, 24, 512, 4, 6 mo1,548E (study 017)6, 24, 5111-181,437
    The PhilippinesPHiD-CV + DTPw-HBV/Hib + OPV; 7vCRM + DTPw-HBV/Hib + OPVC (study 012)2, 6, 246, 10, 14 wk400F (study 018)112-18373
    PolandPHiD-CV + DTPw-HBV/Hib + IPV; 7vCRM + DTPw-HBV/Hib + IPV2, 4, 6 mo40612-18383
Experimental vaccine study (Czech Republic, Slovakia)11Pn-PD + DTPa-HBV-IPV/Hib; HAV + DTPa-HBV-IPV/HibG (POET)33, 35, 36, 42, 433, 4, 5, 12-15 mo4,968
  • a DTPa, diphtheria-tetanus-acellular pertussis; DTPw, diphtheria-tetanus-whole-cell pertussis; HAV, hepatitis A virus; HBV, hepatitis B virus; Hib, Haemophilus influenzae type b; IPV, inactivated poliovirus; MenC-TT, meningococcal C vaccine conjugated to tetanus toxoid; MenC-CRM; meningococcal C vaccine conjugated to CRM197; OPV, oral live attenuated poliovirus vaccine. All vaccines were manufactured by GlaxoSmithKline Biologicals except for MenC-TT (Baxter Healthcare, Zürich, Switzerland), 7vCRM (Pfizer, Inc.), and MenC-CRM (Pfizer, Inc.).